Acutus Medical (NASDAQ:AFIB – Get Free Report) is anticipated to issue its results on Friday, November 13th. Analysts expect Acutus Medical to announce earnings of ($0.95) per share and revenue of $2.79 million for the quarter.
Acutus Medical Price Performance
NASDAQ AFIB opened at $0.00 on Thursday. Acutus Medical has a 1-year low of $0.00 and a 1-year high of $0.01. The stock has a market capitalization of $2,991.20, a PE ratio of -0.00 and a beta of 5.71.
About Acutus Medical
Acutus Medical, Inc. was a medical technology company focused on developing products for the diagnosis and treatment of cardiac arrhythmias, particularly atrial fibrillation. The company’s technologies were designed for use by cardiac electrophysiologists during minimally invasive catheter-based procedures. Its primary product platform was the AcQMap High Resolution Imaging and Mapping System, which combined ultrasound imaging with electrical mapping to create three-dimensional models of the heart and help physicians identify abnormal electrical activity.
Read More
- Five stocks we like better than Acutus Medical
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Acutus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acutus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
